Brisk walks could cut risk of death for colon cancer patients by more than a third, study finds
The results, unveiled at the American Society of Clinical Oncology (ASCO) conference on Sunday, could transform how colon cancer is treated around the world, the researchers said.
The scientists hope the findings will prompt healthcare providers to integrate exercise plans into routine cancer care.
The CO21 CHALLENGE trial, published in the New England Journal of Medicine, followed 889 people with colon cancer across six countries, including the UK.
It found that a structured exercise programme significantly reduced the likelihood of the disease returning and improved overall survival compared with standard advice.
After five years, 80 per cent of patients who followed a tailored exercise regime were cancer-free, compared with 74 per cent of those who were offered just health education materials.
This means the risk of dying, cancer coming back, or developing a new cancer was 28 per cent lower in the exercise group.
After eight years, survival rates were 90 per cent in the exercise group compared to 83 per cent in the health education group, representing a 37 per cent lower risk of death.
More than 31,000 people in the UK die from colon cancer every year, according to Cancer Research UK.
The study was part-funded by Cancer Research UK's Stand Up To Cancer campaign and carried out in collaboration with the Canadian Cancer Trials Group (CCTG).
The three-year programme saw patients supported by physical activity consultants, starting with weekly in-person sessions for the first six months and moving to monthly sessions either in person or online. Activities were tailored to the individual, from brisk walking to gym-based circuit training.
Among the patients to benefit from the trial was Margaret Tubridy, 69, from north Belfast.
Before her cancer diagnosis, she said she had never exercised. Now, five years on, she says she is lifting weights, pole walking and taking part in gym classes twice a week.
'It's been almost five years since my cancer diagnosis and if I meet anyone, I tell them I am doing great,' she said.
'Taking part in the trial helped me so much – I am stronger, fitter, and my anxiety is better. I never thought at 69 years of age I would be able to do all of this – I am chuffed to bits.'
Professor Vicky Coyle, UK lead researcher and clinical professor at Queen's University Belfast, said the study gives 'clear and encouraging' evidence that physical activity can reduce colon cancer mortality.
'We now need to work with policymakers and healthcare providers to embed exercise into treatment plans where appropriate,' she said.
Cancer Research UK said the findings should act as a wake-up call for health services, adding it could 'transform clinical practice'.
However, Caroline Geraghty, senior specialist information nurse at the charity, said this can only happen 'if health services have the necessary funding and staff to make it a reality for patients'.
She added: 'It's important to remember that every cancer journey is different – starting new activities after treatment can feel overwhelming, and it may not be the right option for everyone. Take things at your own pace and speak to your doctor to discuss what is safe for you.'
The researchers said more work is needed to explore the biological mechanisms behind exercise's effect on cancer, but the evidence is already strong enough to prompt urgent action.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
Britons smoke an estimated 28.6 billion cigarettes every year, study finds
An estimated 28.6 billion cigarettes are smoked in Britain each year, the equivalent of 78 million a day, according to new analysis. There are particularly high levels of consumption in more disadvantaged areas, with researchers calling for targeted public health efforts to tackle smoking rates. Charities warned the 'staggering figure' is a 'stark reminder of the deadly toll of inaction', and urged the Government to prioritise the Tobacco and Vapes Bill after Parliament's summer recess. The Cancer Research UK study, carried out by experts at University College London (UCL), used monthly Smoking Toolkit Study data from between 2022 and 2024. The analysis estimates adults who smoked consumed an average of 10.4 cigarettes per day, with 5.5% of those smoking more than 20 a day. Average consumption per smoker per year was 528 cigarettes, equating to 28.6 billion per year. Office for National Statistics (ONS) data suggests 11.9% adults in the UK – the equivalent of six million people – smoked in 2023, the lowest proportion since current records began in 2011. However, England could struggle to meet its smokefree target of 5% by 2030 if current trends continue, according to Cancer Research UK, with projections suggesting it may not be met until 2039. The study also highlighted inequalities in cigarette consumption in Britain. People from more deprived backgrounds smoked 11 cigarettes a day on average, compared to those in wealthier areas, who smoked 9.4 per day. Researchers also found people in the North East and Scotland smoked the most – 11.7 each – while people in London and the South West smoked the least, with 8.4 and 9.5 cigarettes respectively. Dr Sarah Jackson, research fellow at UCL's Institute of Epidemiology and Health Care, said bringing down consumption rates can improve public health and also help the environment. 'Tackling smoking is not just about preventing uptake among future generations,' she said. 'Supporting the six million people in the UK who currently smoke cigarettes to quit will have major benefits for public health and for the environment. 'Despite declining smoking rates, over 28 billion cigarettes are still consumed in Great Britain each year, generating up to 140,000 metric tons of toxic, non-biodegradable waste annually. 'Reducing cigarette consumption, particularly in the most affected regions and communities, is critical not only to save lives and narrow health inequalities, but also to protect our environment from one of the most pervasive forms of plastic pollution.' Dr Ian Walker, executive director of policy at Cancer Research UK, said: 'While great strides have been made to bring down smoking rates, we can't afford to be complacent. 'Every week, around 550 million cigarettes are still smoked in Britain – that's enough to fill an Olympic sized swimming pool. It's vital that everyone, wherever they live, can access the support they need to quit smoking for good.' Dr Walker described the Tobacco and Vapes Bill as 'a historic opportunity to help stub out the harms of smoking' but said it is frustrating the the legislation 'isn't progressing through Parliament as quickly as it should be'. The legislation – which cleared the House of Commons in March – will prevent anyone born on or after January 1 2009 from legally smoking if it becomes law. It is set to undergo further scrutiny in the House of Lords. However, around 20 billion cigarettes have been smoked in Britain since the bill was reintroduced in Commons in November last year, according to the analysis. Dr Walker added: 'Tobacco is a toxic product that should have no place in our future, and I urge all parliamentarians to back a smokefree UK and prioritise this Bill when it returns to the House of Lords. 'This world-leading legislation has strong political and public support that can't be ignored.' Reacting to the study, Hazel Cheeseman, chief executive of Action on Smoking and Health (Ash), said: 'Since Parliament last debated the Tobacco and Vapes Bill, an estimated 6.7 billion cigarettes have been smoked in the UK. 'That staggering figure is a stark reminder of the deadly toll of inaction. Every day that passes without this legislation is a day lost in protecting our children from addiction and improving public health. 'We urge the Government to make this Bill a priority immediately after summer recess. The country cannot afford further delay – this is a once-in-a-generation opportunity to create a smokefree future, and it must not be squandered.'
Medscape
5 days ago
- Medscape
Expanding Treatment Options for Ovarian Cancer
This transcript has been edited for clarity. My name is Brian Slomovitz. I'm a gynecologic oncologist and I look forward to presenting some of the recent trends in ovarian cancer management, what we're doing to better treat our patients, and some of the latest updates from the ASCO 2025 meeting. Let's talk about surgery. Until now, studies haven't shown a statistical difference between neoadjuvant chemotherapy followed by interval debulking and upfront primary debulking surgery for the management of this disease. At this year's ASCO meeting, the TRUST trial was presented. It looked at furthering the role of upfront surgery vs neoadjuvant chemotherapy. This was a well-balanced study conducted at leading surgical centers throughout Europe and the United States, with overall survival as the primary endpoint. Unfortunately, the trial was negative: There was no improvement in overall survival for patients who underwent primary debulking surgery compared to those who had interval debulking surgery after neoadjuvant chemotherapy. There was a benefit in progression-free survival, but that wasn't the primary endpoint. We're looking forward to future research that may further answer this question, but as of now, primary debulking surgery hasn't demonstrated a survival advantage. We'll have to see how this continues to evolve. Turning to primary systemic therapy, there have been several recent studies looking at the addition of checkpoint inhibitors to standard chemotherapy — with or without bevacizumab and PARP inhibitors — to determine whether this could improve outcomes. One of the key studies presented at this year's meeting was the FIRST trial. It was a well-designed trial, with an appropriate control arm using standard therapies and adding immunotherapy in the experimental arm. This study did show a statistically significant improvement. However, when we talk about clinically meaningful, are we going to put that into our practice? The difference was only 1 month. Although this was statistically significant, it is unclear whether this finding will change clinical practice at this point. In the recurrent setting, a great unmet need is better treatment options for our patients with platinum-resistant disease. One recent advance is mirvetuximab, an antibody-drug conjugate targeting the folate receptor alpha. This therapy demonstrated a positive overall survival benefit, but it applies only to a subset of patients who overexpress this receptor protein. Also at this year's ASCO meeting, results from the ROSELLA trial were presented. All patients received nab-paclitaxel, an active agent for recurrent ovarian cancer, and the experimental arm included the addition of relacorilant, a glucocorticoid receptor. The study showed a statistically significant improvement in progression-free survival among patients treated with relacorilant. There was also a clinically meaningful trend toward improved overall survival associated with the addition of relacorilant. Although the data are not yet mature, we may see this combination become increasingly significant over time. The findings were published on the same day in The Lancet . If the sponsors move forward with a regulatory strategy, this could become part of the standard of care — potentially making a real, day-to-day difference for our patients. Another exciting development in the management of recurrent disease is IL-2 gene therapy. At this meeting, Dr Premal Thaker presented results from the OVATION 2 trial, which showed a strong response rate and a promising signal in patients with ovarian cancer. I think the logical next step would be a phase 3 registrational trial to determine whether this IL-2 gene therapy can ultimately be incorporated into the standard of care for our patients. We're making significant strides in the management of ovarian cancer, and I believe ongoing and future studies will continue to improve outcomes and help our patients live longer with a good quality of life.
Yahoo
15-07-2025
- Yahoo
Mum-of-two wants to find stranger who 'saved her life' in work meeting
A cancer researcher who developed the disease herself is hoping to find the stranger who saved her life. Emma Hawke was at a work meeting when a dermatologist she had never met before spotted a suspicious mole on her arm and urged her to get it checked. She was subsequently diagnosed with melanoma - the most serious form of skin cancer. Cancer researcher Emma Hawke was at a work meeting when a doctor spotted a suspicious mole on her arm (Image: Cancer Research UK) Emma, a 42-year-old mother-of-two from Eastleigh, said: "I was watching TV when the phone rang. I thought it was going to be a family member calling, but it was the hospital. "My melanoma diagnosis was a huge shock and I immediately expected to need chemotherapy or immunotherapy. "My sons were just five and eight at the time and I feared they were going to see me becoming really poorly. 'Thankfully it was caught early enough to be managed with surgery and it hadn't spread to my lymph nodes. "I do have a scar on my arm where they had to take a large enough area of skin to safely remove all the cancerous cells, but I would have gone through so much more treatment or worse had I left it. "I would love to find the doctor who spotted it and say thanks for saving my life." Former skin cancer patient Emma Hawke is urging people to stay safe by using plenty of sun cream (Image: Getty Images) Emma is also working to raise awareness of skin cancer. She has joined forces with Cancer Research UK and NIVEA Sun to encourage people across the south to seek shade, cover up, and apply sunscreen regularly. "Awareness of the risks of UV radiation was low when I was younger, and I'd put oil on try to look tanned like the popstars of the 90s," she said. 'Now, I make sure I'm covered up and take some time out of the sun in the middle of the day as well as always being prepared with a hat, sunglasses, and sunscreen. "Sun safety doesn't mean missing out, just being careful whether you're at home or abroad.' READ MORE: Southampton cancer vaccine trial expands for melanoma patients Cancer Research UK health information manager Beth Vincent added: "Getting sunburnt just once every two years can triple the risk of developing skin cancer compared to never being burnt. "Even on a cloudy day, the sun can be strong enough to burn between mid-March and mid-October."
